Notably, adipocyte treatment with Atglistatin had no effect on CA9, VEGF or GLUT1 expression in PC3 cells (Supplementary Figure 10B), suggesting that inhibition of adipocyte lipolysis is not sufficient to reverse adipocyte-driven HIF-1α activation in tumor cells and offers a potential explanation for the persisting glycolytic phenotype. Here, SLC2A1 is linked to neoplasm.